Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -14.60% is 12% above its 5-year average of -16.60%, near the high end of its 5-year range (-34.58%–-11.11%).
As of the fiscal period ended Tuesday, June 30, 2026. 18.85% above its 12-month average of -17.99%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -14.60%.
RETURN ON EQUITY (ROE)
-14.60%
RETURN ON EQUITY (ROE) AVG TTM
-17.99%
RETURN ON EQUITY (ROE) AVG 3Y
-16.36%
RETURN ON EQUITY (ROE) AVG 5Y
-16.60%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+18.85%
CURRENT VS 3Y AVG
+10.76%
CURRENT VS 5Y AVG
+12.07%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.57%
median of 507 covered companies
CURRENT VS SECTOR MEDIAN
+62.15%
vs the sector median at left
IDEAYA Biosciences, Inc.
Market Cap
$3.49B
Return on Equity (ROE)
-14.60%
TTM Avg
-17.99%
3Y Avg
-16.36%
5Y Avg
-16.60%
Market Cap
$3.46B
Return on Equity (ROE)
26.08%
TTM Avg
3.42%
3Y Avg
-20.94%
5Y Avg
-16.18%
Market Cap
$3.45B
Return on Equity (ROE)
N/A
TTM Avg
-136.37%
3Y Avg
-87.14%
5Y Avg
-78.77%
Market Cap
$3.55B
Return on Equity (ROE)
-7.50%
TTM Avg
-76.90%
3Y Avg
-65.24%
5Y Avg
-51.68%
Market Cap
$3.42B
Return on Equity (ROE)
29.12%
TTM Avg
31.38%
3Y Avg
-1.34%
5Y Avg
-13.55%
Market Cap
$3.04B
Return on Equity (ROE)
12.93%
TTM Avg
-48.70%
3Y Avg
-135.42%
5Y Avg
-110.19%
Market Cap
$3.03B
Return on Equity (ROE)
-61.24%
TTM Avg
-42.47%
3Y Avg
-32.58%
5Y Avg
-25.72%
Market Cap
$3.03B
Return on Equity (ROE)
-63.59%
TTM Avg
-115.27%
3Y Avg
-69.35%
5Y Avg
-25.98%
Market Cap
$2.99B
Return on Equity (ROE)
-11.83%
TTM Avg
-25.64%
3Y Avg
-7.84%
5Y Avg
-12.83%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | $3.49B | -14.60% | -17.99% | -16.36% | -16.60% |
| CareDx, Inc (CDNA)vs › | $3.46B | 26.08% | 3.42% | -20.94% | -16.18% |
| Celcuity Inc. (CELC)vs › | $3.45B | N/A | -136.37% | -87.14% | -78.77% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.55B | -7.50% | -76.90% | -65.24% | -51.68% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.42B | 29.12% | 31.38% | -1.34% | -13.55% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.04B | 12.93% | -48.70% | -135.42% | -110.19% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.03B | -61.24% | -42.47% | -32.58% | -25.72% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.03B | -63.59% | -115.27% | -69.35% | -25.98% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $2.99B | -11.83% | -25.64% | -7.84% | -12.83% |
| ICU Medical, Inc. (ICUI)vs › | $3.95B | 1.40% | -2.98% | -2.73% | 0.21% |
ROE
-14.6%
ROA
-13.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -14.60% |
| 2026-03-31 | -14.94% |
| 2025-12-31 | -11.11% |
| 2025-09-30 | -14.72% |
| 2025-06-30 | -34.58% |
| 2025-03-31 | -29.98% |
| 2024-12-31 | -25.91% |
| 2024-09-30 | -15.09% |
| 2024-06-30 | -16.50% |
| 2024-03-31 | -13.78% |
| 2023-12-31 | -18.19% |
| 2023-09-30 | -20.31% |
| 2023-06-30 | -14.78% |
| 2023-03-31 | -20.46% |
| 2022-12-31 | -16.78% |
| 2022-09-30 | -14.28% |
| 2022-06-30 | -24.46% |
| 2022-03-31 | -18.97% |
| 2021-12-31 | -16.50% |
| 2021-09-30 | -11.55% |
| 2021-06-30 | -12.50% |
| 2021-03-31 | -13.50% |
| 2020-12-31 | -17.40% |
| 2020-09-30 | -20.54% |
| 2020-06-30 | -26.84% |
| 2020-03-31 | -49.88% |
| 2019-12-31 | -41.81% |
| 2019-09-30 | -36.01% |
| 2019-06-30 | -34.69% |
| 2019-03-31 | -47.53% |
